Anzeige
Mehr »
Freitag, 06.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QCUH | ISIN: SE0014855029 | Ticker-Symbol: 8IM1
Düsseldorf
06.06.25 | 09:10
3,735 Euro
-0,93 % -0,035
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
IMPLANTICA AG SDR Chart 1 Jahr
5-Tage-Chart
IMPLANTICA AG SDR 5-Tage-Chart
RealtimeGeldBriefZeit
3,4503,60017:54
3,4003,60016:06
PR Newswire
260 Leser
Artikel bewerten:
(1)

Implantica announces that UK NICE has published positive recommendations for the RefluxStop procedure in the NHS public hospitals

VADUZ, Liechtenstein, June 4, 2025 /PRNewswire/ -- Implantica AG (publ.), providing the unique device RefluxStop for the treatment of acid reflux, announces that the world-renowned National Institute for Healthcare Excellence (NICE) payer advisory agency for NHS public hospitals in the UK has published positive Interventional Procedures Guidance (IPG) recommendations on the RefluxStop procedure, wherein GORD/GERD patients with Ineffective Oesophageal Motility (IOM/IEM) are allowed to be operated with RefluxStop procedure in the public healthcare system, following its guidelines and special arrangements.

In the treatment field of acid reflux up to 40-50%1 of the 1 billion sufferers have IOM/IEM. Therefore, NICE IPG recommendations could transform the lives of millions of patients in the UK and worldwide, given NICE's global influence on health policy development. The IOM/IEM condition is largely untreatable with traditional standard of care.

Mr. Ahmed Ahmed, Consultant Surgeon at St. Mary's Hospital, Imperial College NHS Health Trust says, "The positive NICE guidance for use of RefluxStop is a major victory for GORD patients. This decision empowers NHS Anti-Reflux Surgeons to continue delivering cutting-edge care while contributing to the growing body of evidence supporting RefluxStop procedure as a transformative solution for GORD. My patients have heard about RefluxStop procedure as they seek a solution for GORD and ask for it specifically by name. It will be very reassuring for GORD patients to have this supporting evidence-based guidance."

Another leading surgeon in the NHS public hospitals, Mr. Fergus Noble, Consultant Surgeon at University Hospital Southampton NHS Foundation Trust, adds, "NICE's new guidelines are crucial for the broader use of a new procedure in the NHS. I'm proud to be a part of this important step forward in expanding the landscape of anti-reflux surgical options for patients with GORD and IOM. Unlike traditional anti-reflux surgeries, the RefluxStop procedure does not rely on encircling the oesophagus, making the durable benefits of a surgical treatment for GORD available to desperate patients who have struggled with the painful symptoms of combined GORD and IOM with poor motility for years."

Inventor of the RefluxStop procedure, CEO and Founder of Implantica, Dr. Peter Forsell says, "We would like to thank NICE for their independent multidisciplinary assessment of the RefluxStop procedure and invaluable efforts to recognize the excellent safety and efficacy of the innovative RefluxStop procedure for use in NHS public hospitals. This recommendation for GORD/GERD patients with IOM marks the start of a global paradigm shift in the surgical treatment of acid reflux, with the NHS UK taking the lead."

1. Shih-Chi Ho et al., Ineffective esophageal motility is a primary motility disorder in gastroesophageal reflux disease. Digestive Diseases and Sciences, 2002. 47(3): 652-6

For further information, please contact:
Nicole Pehrsson, Chief Corporate Affairs Officer
Telephone (CH): +41 (0)79 335 09 49
nicole.pehrsson@implantica.com

Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm.

The company's Certified Adviser is FNCA Sweden AB, info@fnca.se

The information was sent for publication, through the agency of the contact person set out above, on June 04, 2025, at 08:00 a.m. (CET).

About Implantica

Implantica is a medtech group dedicated to bringing advanced technology into the body. Implantica's lead product, RefluxStop, is a CE-marked implant for the prevention of gastroesophageal reflux that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results. Implantica also focuses on eHealth inside the body and has developed a broad, patent protected, product pipeline based partly on two platform technologies: an eHealth platform designed to monitor a broad range of health parameters, control treatment from inside the body and communicate to the caregiver on distance and a wireless energizing platform designed to power remote-controlled implants wirelessly through intact skin. Implantica is listed on Nasdaq First North Premier Growth Market (ticker: IMP A SDB). Visit www.implantica.com for further information.

About RefluxStop

RefluxStop is a new innovative treatment that has the potential to spur a paradigm shift in anti-reflux surgery. It's unique mechanism of action differentiates it from standard of care and current surgical solutions. Longer established surgical options for GORD involve encircling the food passageway to support the lower oesophageal sphincter's closing mechanism and are commonly associated with side effects such as swallowing difficulties, pain when swallowing and inability to belch and/or vomit.

In contrast, the RefluxStop device treats the cause of acid reflux without encircling and putting pressure on the food passageway. It restores and maintains the lower oesophageal sphincter in its original, natural position.

The RefluxStop mechanism of action is focused on reconstructing all three components of the anti-reflux barrier, that if compromised could possibly result in acid reflux. It restores and supports the natural anatomical physiology of the body allowing the body to itself solve the problem with acid reflux.

Newsroom
https://www.implantica.com/media/media-kit

Community
https://ch.linkedin.com/company/implantica
https://www.twitter.com/implantica

Media Contact:
Implantica AG
Juanita Eberhart, VP Marketing & Advocacy
M: +1 925-381-4581
juanita.eberhart@implantica.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/implantica/r/implantica-announces-that-uk-nice-has-published-positive-recommendations-for-the-refluxstop--procedu,c4158795

The following files are available for download:

https://mb.cision.com/Main/19732/4158795/3485992.pdf

Implantica announces that UK NICE has published positive recommendations for the RefluxStop procedure in the NHS public Hospitals

https://news.cision.com/implantica/i/logo-transparent-1-8,c3415114

logo transparent 1 8

https://news.cision.com/implantica/i/reluxstop-product,c3415115

ReluxStop Product

Cision View original content:https://www.prnewswire.co.uk/news-releases/implantica-announces-that-uk-nice-has-published-positive-recommendations-for-the-refluxstop-procedure-in-the-nhs-public-hospitals-302472913.html

© 2025 PR Newswire
Die USA haben fertig! 5 Aktien für den China-Boom
Die Finanzwelt ist im Umbruch! Nach Jahren der Dominanz erschüttert Donald Trumps erratische Wirtschaftspolitik das Fundament des amerikanischen Kapitalismus. Handelskriege, Rekordzölle und politische Isolation haben eine Kapitalflucht historischen Ausmaßes ausgelöst.

Milliarden strömen aus den USA – und suchen neue, lukrative Ziele. Und genau hier kommt China ins Spiel. Trotz aller Spannungen wächst die chinesische Wirtschaft dynamisch weiter, Innovation und Digitalisierung treiben die Märkte an.

Im kostenlosen Spezialreport stellen wir Ihnen 5 Aktien aus China vor, die vom US-Niedergang profitieren und das Potenzial haben, den Markt regelrecht zu überflügeln. Wer jetzt klug investiert, sichert sich den Zugang zu den neuen Wachstums-Champions von morgen.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche 5 Aktien die Konkurrenz aus den USA outperformen dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.